Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Hong Kong Med J ; 17(4): 280-5, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21813895

ABSTRACT

OBJECTIVE: To review the site of involvement, clinical presentation, and treatment outcome of patients having immunoglobulin G4-related sclerosing disease in a local regional hospital. DESIGN: Retrospective case series. SETTING: Pamela Youde Nethersole Eastern Hospital, Hong Kong. PATIENTS: All patients with a diagnosis of immunoglobulin G4-related sclerosing disease in the hospital diagnosed in the period from April 2008 to March 2010. RESULTS: A total of 12 patients with involvement of various organs were identified. There was a male predominance (male-to-female ratio=5:1). The mean age at diagnosis was 65 years. The salivary glands, biliary tract, pancreas, and cervical lymph nodes were the commonest involved sites. The immunoglobulin G4 level was elevated in 83% of the patients. Patients usually appeared to respond well to steroid treatment. CONCLUSION: Immunoglobulin G4-related sclerosing disease is a systemic disease and can involve various systems.


Subject(s)
Immunoglobulin G/blood , Sclerosis/immunology , Adrenal Cortex Hormones/therapeutic use , Aged , Female , Humans , Male , Retrospective Studies , Sclerosis/drug therapy , Treatment Outcome
2.
Hong Kong Med J ; 16(6): 463-9, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21135423

ABSTRACT

OBJECTIVE: To test our hypothesis that there is inadequate knowledge and awareness of hepatitis B infection among the general population in Hong Kong. DESIGN: A random telephone survey using a structured multiple-choice questionnaire. SETTING: Hong Kong community. PARTICIPANTS: Hong Kong residents aged 18 years or above. RESULTS: A total of 506 respondents were successfully interviewed in February 2010. Approximately half of respondents (55%) were aware that hepatitis B virus is the most common cause of chronic viral hepatitis in Hong Kong. Regarding knowledge about the mode of transmission, mother-to-infant transmission and blood contact were recognised as risk factors by 67% and 65% of respondents, respectively. Transmission by sexual contact, sharing a razor or toothbrush, and tattooing or body piercing were appreciated by 44%, 41%, and 37% of respondents, respectively. A majority (73%) had the mistaken belief that the virus is transmitted by eating contaminated seafood. Over half of respondents (53%) knew nothing about the clinical presentation of acute hepatitis B. Only 35% of respondents realised that periodic abdominal ultrasonographic examinations are indicated for asymptomatic hepatitis B carriers. While 51% of respondents reported being tested for hepatitis B virus infection, only 36% acknowledged being vaccinated against the infection. Education level, occupation, and marital status were factors associated with both hepatitis B virus screening and vaccination. CONCLUSION: These findings support our hypothesis that there is inadequate knowledge and awareness about hepatitis B infection in the general population in Hong Kong.


Subject(s)
Health Knowledge, Attitudes, Practice , Hepatitis B/prevention & control , Adolescent , Adult , Aged , Aged, 80 and over , Female , Hepatitis B/transmission , Humans , Male , Middle Aged , Surveys and Questionnaires , Telephone , Vaccination
4.
Acta Gastroenterol Belg ; 68(4): 428-31, 2005.
Article in English | MEDLINE | ID: mdl-16432995

ABSTRACT

Haemobilia denotes an abnormal communication between a vessel of the splanchnic circulation and the biliary system. Patients typically presents with the triad of abdominal pain, upper gastrointestinal haemorrhage, and jaundice. Common causes for haemobilia are iatrogenic causes secondary to hepatobiliary system instrumentation and trauma. Management of patients with haemodynamic significant haemobilia is aimed at stopping bleeding, maintaining continuous flow of biliary system, and cure of the underlying aetiology. Iatrogenic haemobilia after ERCP polyethylene biliary endoprosthesis placement is extremely uncommon. Herein we present a case of iatrogenic haemobilia triggered by biliary endoprosthesis placement and was successfully managed by non-operative treatment. The management algorithm for a rational approach to haemobilia is discussed.


Subject(s)
Cholangiopancreatography, Endoscopic Retrograde/methods , Choledocholithiasis/surgery , Embolization, Therapeutic/methods , Hemobilia/etiology , Hemobilia/therapy , Prostheses and Implants/adverse effects , Angiography/methods , Choledocholithiasis/diagnostic imaging , Follow-Up Studies , Hemobilia/diagnostic imaging , Humans , Iatrogenic Disease , Male , Middle Aged , Risk Assessment , Tomography, X-Ray Computed/methods , Treatment Outcome
5.
Gastrointest Endosc ; 54(4): 454-8, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11577306

ABSTRACT

BACKGROUND: A "test-and-treat" strategy for H pylori infection has been recommended in Europe and North America as safe and cost-effective for management of patients with dyspepsia. The primary aim of this study was to determine the frequency of gastroesophageal cancer in 2 groups of patients with dyspepsia: those 45 years of age or younger without "alarm" symptoms (low-risk group) and patients over 45 years of age or any patient with "alarm" symptoms (high-risk group). A secondary aim was to determine the frequency of gastric cancer among patients in the low-risk group with or without a positive serology for H pylori. METHODS: Patients with persistent dyspepsia were recruited from 4 regional hospitals in Hong Kong. Those in the low-risk group were evaluated for H pylori by using a whole blood serology test; they underwent endoscopy within 1 week. Those in the high-risk group and those taking nonsteroidal anti-inflammatory drugs (NSAIDs) underwent endoscopy promptly. Alarm symptoms were as follows: weight loss (10 or more pounds over 8 weeks), recurrent vomiting, dysphagia, bleeding, or anemia. RESULTS: Of 2627 patients enrolled, 1017 were in the low-risk group and 1610 in the high-risk group. Twenty-three patients (0.9%) had gastroesophageal cancers (20 gastric, 3 esophageal). Four patients with cancer (17.4%) were in the low-risk group (3 gastric, 1 esophageal); all except the patient with esophageal cancer had a positive serology test. In the high-risk group, 19 patients had cancer (17 gastric, 2 esophageal). CONCLUSION: Gastric cancer is relatively frequent among young patients with dyspepsia who have no alarm features in Hong Kong. This finding raises concerns as to the safety of the "test-and-treat" strategy for the management of patients with dyspepsia in Asia.


Subject(s)
Dyspepsia/epidemiology , Esophageal Neoplasms/epidemiology , Stomach Neoplasms/epidemiology , Adult , Female , Hong Kong/epidemiology , Humans , Incidence , Male , Middle Aged , Prospective Studies , Risk Assessment
6.
Surg Endosc ; 15(2): 218, 2001 Feb.
Article in English | MEDLINE | ID: mdl-12200663

ABSTRACT

Situs inversus is a rare anomaly with a genetic predisposition. We report a patient with situs inversus, cholelithiasis, and choledocholithiasis who was treated successfully with laparoscopic cholecystectomy and laparoscopic exploration of the common bile duct. We believe this to be the first such case reported in the literature.


Subject(s)
Cholecystectomy, Laparoscopic/methods , Cholecystitis/surgery , Gallstones/surgery , Situs Inversus/surgery , Aged , Female , Humans
7.
Hong Kong Med J ; 5(2): 187-190, 1999 Jun.
Article in English | MEDLINE | ID: mdl-11821590

ABSTRACT

To survey the practice patterns of physicians in public hospitals in Hong Kong when treating Helicobacter pylori-associated peptic ulceration, the records of all patients from 22 medical units who had new peptic ulcers that had been diagnosed endoscopically during August 1996 were examined systematically. Patient data were entered on a one-page questionnaire. Five hundred and twelve patients with peptic ulceration were studied; 173 (34%) of whom had presented with gastro-intestinal bleeding. The Helicobacter pylori status had been determined in 449 (88%) patients, 280 (62%) of whom had subsequently tested positive for Helicobacter pylori. The biopsy urease test or histological examination had been performed for more than 95% of patients. Of 260 patients who had tested positive for Helicobacter pylori, 244 (94%) had received eradication therapy to eliminate this organism; a total of 291 patients, however, were receiving eradication therapy. The most commonly used regimen was proton pump inhibitor triple therapy (151 [52%] of 291 patients). Confirmation of the eradication of Helicobacter pylori had been planned for 152 (52%) of the 291 patients, whereas ulcer-healing drugs--mainly H2-receptor antagonists--had been prescribed for 87 (30%) patients after eradication. Curing Helicobacter pylori infection is therefore widely accepted in the management of peptic ulcer disease among physicians working in Hong Kong public hospitals.

8.
Gut ; 34(3): 338-42, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8472980

ABSTRACT

Ranitidine bismuth citrate was compared with an equipotent dose of ranitidine, to determine whether the former, by an anti-Helicobacter pylori activity, would counteract the rise of gastrin resulting from ranitidine's gastric acid antisecretory activity. Twenty four men with duodenal ulcers were studied before and on the 8th day of dosing with either ranitidine bismuth citrate 800 mg twice daily or ranitidine 300 mg twice daily (double blind, randomised, parallel groups). Fasting and postprandial plasma gastrin and plasma pepsinogen I and II concentrations were measured, and a 13C-urea breath test was performed before and on the 8th day of dosing. The 13C-urea breath tests were positive in 21 patients before dosing and remained positive in nine of nine of the ranitidine dosed patients, whereas only two of 12 patients treated with ranitidine bismuth citrate remained positive. The expected rise in meal stimulated plasma gastrin with ranitidine was seen in the 12 patients who received ranitidine but, despite suppression of H pylori urease activity in 10 of 12 patients taking ranitidine bismuth citrate, there was no attenuation of the meal stimulated gastrin rise. There was no significant difference in the mean derived (4 hour) plasma pepsinogen I and II concentrations after dosing with ranitidine or ranitidine bismuth citrate.


Subject(s)
Bismuth/therapeutic use , Citrates/therapeutic use , Gastrins/blood , Pepsinogens/blood , Ranitidine/analogs & derivatives , Adult , Aged , Breath Tests , Duodenal Ulcer/blood , Duodenal Ulcer/drug therapy , Food , Humans , Male , Middle Aged , Organometallic Compounds/therapeutic use , Ranitidine/therapeutic use , Time Factors
9.
Aliment Pharmacol Ther ; 6(1): 97-102, 1992 Feb.
Article in English | MEDLINE | ID: mdl-1543820

ABSTRACT

Assessment of intragastric urease activity by the 13C-urea breath test was performed before and after one day of dosing with either De-Noltabs (tripotassium dicitrato bismuthate, one tablet 1 q.d.s.), Pepto-Bismol liquid (bismuth salicylate 30 ml q.d.s.), or Roter tablets (bismuth subnitrate, one tablet q.d.s.) in twelve Helicobacter pylori-positive patient volunteers. There was a significant decrease in the excess of 13CO2 after one day of dosing with each of the three bismuth compounds, but analysis of variance could detect no difference between the effects of the three compounds. Systemic absorption of bismuth following oral dosing with either Pepto-Bismol or Roter is minimal, yet both compounds have a suppressive effect on H. pylori similar to that of De-Noltab. This study suggests that the action of all three bismuth compounds is within the gastric lumen, and that systemic absorption of bismuth is not necessary for activity against H. pylori.


Subject(s)
Bismuth/pharmacology , Gastric Mucosa/microbiology , Helicobacter pylori/drug effects , Organometallic Compounds/pharmacology , Salicylates/pharmacology , Adult , Aged , Analysis of Variance , Bismuth/administration & dosage , Breath Tests , Carbon Dioxide/analysis , Female , Gastric Mucosa/drug effects , Helicobacter pylori/enzymology , Humans , Male , Middle Aged , Organometallic Compounds/administration & dosage , Salicylates/administration & dosage , Urea , Urease/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...